AUTHORS
Samer A Srour, MB ChB, MS, Auris O. Huen, MD, PharmD2, Yago Nieto, MD, Ph.D3, Bouthaina S. Dabaja, MD4, Ranjit Nair, MD5, Jeremy Ramdial, MD6, Luis Malpica, MD7, Luis E. Fayad, MD8, Carlos Torres-Cabala, MD9, Jessie Xu, Associate Professor10, Jillian R. Gunther, MD PhD11, Uday Popat, MD, MBA12, Partow Kebriaei, MD13, Muzaffar Qazilbash, MD14, Madeleine Duvic, MD15, Nicole LeBoeuf16, Richard Champlin17, Elizabeth Shpall, MD18, Swaminathan P. Iyer, MD19, Chitra Hosing, MD20
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction
Patients with relapsed/refractory advanced cutaneous T-cell lymphomas (CTCLs) have limited treatment options that are known to confer long-term disease control. Allogeneic stem cell transplantation (Allo-SCT) remains the only potentially curative treatment. We report on our long-term experience with allo-SCT and explore predictive factors for better outcomes.
Methods
All consecutive patients with CTCL who underwent allogeneic SCT between July 2001 and April 2025 were included. The primary objectives of the study were progression-free survival (PFS) and overall survival (OS). Secondary objectives included exploration of risk factors that impact transplant outcomes. Kaplan-Meier method was used to estimate OS and PFS. Cox regression analyses were used to determine prognostic factors. Cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were determined using the competing risks method.
Results
A total of ninety-seven patients (males, 55%) with a median age of 53 (range, 18-72) years were identified during the study period. Mycosis fungoides (MF) was the most frequent subtype (n = 65), followed by Sézary syndrome (SS; n = 26). Six patients had primary cutaneous lymphoproliferative disorder and were excluded from final survival analysis. Thirty-eight patients (39%) had large-cell transformation (LCT). Prior to transplant, 24 patients (27%) had no evidence of disease per TNMB staging; 36 patients (40%) had stage I/II, 4 (4%) stage III, and 10 (11%) and 16 (18%) had stages IVA and IVB, respectively. Patients had received a median of 4 prior lines of therapy, and all except one received total skin electron beam therapy (TSEBT) immediately prior to transplant. Seventy-three patients (75%) received matched related (MRD, n = 39) or unrelated (MUD, n = 34) donor transplant, 12 (13%) had haploidentical donors and 9 (9%) received mismatched MUD (MMUD). Eighty percent of patients received fludarabine/melphalan-based conditioning regimen, and 65% and 33% received MTX-based and PTCy-based GVHD prophylaxis, respectively.
With a median follow-up of 6.4 (range, 0.15-22.83) years, the median PFS and OS were 6 and 42 months, respectively. The 5-year PFS and OS were 29% and 49% respectively. The 5-year cumulative incidence rates of relapse and NRM were 45% and 26%, respectively. The 5-year PFS and OS for SS were 49% and 64% compared to 19% and 38% for MF patients (p=0.046 for PFS; p=0.0681 for OS). Patients with LCT had an inferior PFS of 16% at 5 yrs compared to 37% for patients without LCT (p=0.0215). The 5-year OS was also impacted by donor type; OS at 5 years was 38%, 49% and 70% respectively in those with haploidentical, MUD and MRD donors respectively (p=0.061). Forty-eight patients died during the study period, majority died of relapsed disease (56%), followed by GVHD (17%), infection (15%), second malignancy (10%) and respiratory failure (2%).
Conclusion
For patients with relapsed/refractory CTCL, Allo-SCT results in around 30% long-term disease control and potential cure. Patients with SS and matched donors have better outcomes. Although relapse remains the most frequent cause of treatment failure, a notable proportion of patients can have long term survival after salvage treatment.
DISCLOSURES
Samer A Srour, MB ChB, MS: No relevant conflicts of interest to declare.